Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double Blind, Placebo Controlled Parallel Group, Pilot Study to Assess the Efficacy and Safety of H.P. Acthar Gel in Subjects With Relapsing-remitting Multiple Sclerosis

Next Previous
X
Search
Trial Profile

A Multicenter, Randomized, Double Blind, Placebo Controlled Parallel Group, Pilot Study to Assess the Efficacy and Safety of H.P. Acthar Gel in Subjects With Relapsing-remitting Multiple Sclerosis

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 14 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Corticotropin (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms OPTIONS
  • Sponsors Mallinckrodt Inc.

    • Most Recent Events

    • 15 Oct 2021 Results assessing efficacy and safety of RCI in patients with RRMS experiencing an acute relapse and inadequate response to high-dose corticosteroids presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
    • 14 Jul 2020 Status changed from suspended to discontinued.
    • 30 Apr 2020 Status changed from active, no longer recruiting to suspended.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top